WO2003072056A3 - Intranasal administration of mc4-r agonists - Google Patents

Intranasal administration of mc4-r agonists Download PDF

Info

Publication number
WO2003072056A3
WO2003072056A3 PCT/US2003/005874 US0305874W WO03072056A3 WO 2003072056 A3 WO2003072056 A3 WO 2003072056A3 US 0305874 W US0305874 W US 0305874W WO 03072056 A3 WO03072056 A3 WO 03072056A3
Authority
WO
WIPO (PCT)
Prior art keywords
agonists
intranasal administration
melanocortin
receptor agonist
mammalian subject
Prior art date
Application number
PCT/US2003/005874
Other languages
French (fr)
Other versions
WO2003072056A2 (en
Inventor
Linda Li Xiao
Baoji Xu
Jian Luo
Kirk Johnson
William H Ii Frey
Effie Tozzo
David Duhl
Original Assignee
Chiron Corp
Linda Li Xiao
Baoji Xu
Jian Luo
Kirk Johnson
William H Ii Frey
Effie Tozzo
David Duhl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Linda Li Xiao, Baoji Xu, Jian Luo, Kirk Johnson, William H Ii Frey, Effie Tozzo, David Duhl filed Critical Chiron Corp
Priority to AU2003219914A priority Critical patent/AU2003219914A1/en
Priority to EP03716199A priority patent/EP1487474A4/en
Priority to JP2003570803A priority patent/JP2005524649A/en
Priority to US10/505,159 priority patent/US20070004743A1/en
Publication of WO2003072056A2 publication Critical patent/WO2003072056A2/en
Publication of WO2003072056A3 publication Critical patent/WO2003072056A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A method for delivering a melanocortin-4 receptor agonist to a mammalian subject, includes administering the melanocortin-4 receptor agonist to a tissue inside the nasal cavity or sinuses of the mammalian subject. In some instances, the melanocortin-4 receptor agonist includes a guanidine functional group.
PCT/US2003/005874 2002-02-25 2003-02-25 Intranasal administration of mc4-r agonists WO2003072056A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003219914A AU2003219914A1 (en) 2002-02-25 2003-02-25 Intranasal administration of mc4-r agonists
EP03716199A EP1487474A4 (en) 2002-02-25 2003-02-25 Intranasal administration of mc4-r agonists
JP2003570803A JP2005524649A (en) 2002-02-25 2003-02-25 Intranasal administration of MC4-R agonist
US10/505,159 US20070004743A1 (en) 2002-02-25 2003-02-25 Intranasal administration of mc4-r agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35870002P 2002-02-25 2002-02-25
US60/358,700 2002-02-25
US37292102P 2002-04-16 2002-04-16
US60/372,921 2002-04-16

Publications (2)

Publication Number Publication Date
WO2003072056A2 WO2003072056A2 (en) 2003-09-04
WO2003072056A3 true WO2003072056A3 (en) 2004-06-24

Family

ID=27767549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005874 WO2003072056A2 (en) 2002-02-25 2003-02-25 Intranasal administration of mc4-r agonists

Country Status (5)

Country Link
US (2) US20030229025A1 (en)
EP (1) EP1487474A4 (en)
JP (1) JP2005524649A (en)
AU (1) AU2003219914A1 (en)
WO (1) WO2003072056A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
AU2003219914A1 (en) * 2002-02-25 2003-09-09 Chiron Corporation Intranasal administration of mc4-r agonists
PT1551834E (en) * 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Substituted quinazolinone compounds
US7625909B2 (en) 2003-05-23 2009-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinazolinone compounds
WO2005051391A1 (en) * 2003-11-19 2005-06-09 Chiron Corporation Quinazolinone compounds with reduced bioaccumulation
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
ATE458491T1 (en) 2005-08-26 2010-03-15 Univ Leland Stanford Junior METHOD FOR TREATING HEADACHE BY ADMINISTRATION OF OXYTOCIN
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
US9808509B2 (en) 2007-06-08 2017-11-07 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
US8622993B2 (en) * 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
KR20220119187A (en) 2013-05-15 2022-08-26 리젠츠 오브 더 유니버시티 오브 미네소타 Adeno-associated virus mediated gene transfer to the central nervous system
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
PT3242676T (en) 2015-01-07 2023-12-06 TONIX Pharmaceuticals Holding Corp Magnesium-containing oxytocin formulations and methods of use
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
IL262211B2 (en) 2016-04-15 2024-01-01 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
WO2019241755A2 (en) * 2018-06-15 2019-12-19 Jay Dela Cruz Treatment of synucleinopathy and animal models of synucleinopathy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127381A (en) * 1998-04-28 2000-10-03 Basu; Amaresh Isoquinoline compound melanocortin receptor ligands and methods of using same
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US20020137939A1 (en) * 2000-08-31 2002-09-26 Renhowe Paul A. Novel guanidinobenzamides

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177218A (en) * 1962-01-17 1965-04-06 Monsanto Chemicals Methylene-bis(2-guanidino-4-methylquinazoline)
US4211867A (en) * 1976-03-19 1980-07-08 Mcneil Laboratories, Incorporated Nitrogen heterocyclic carboximidamide compounds
DE2623846A1 (en) * 1976-05-28 1977-12-15 Hoechst Ag 4-QUINAZOLINYL GUANIDINE AND THE METHOD OF MANUFACTURING IT
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
DE3270716D1 (en) * 1981-02-27 1986-05-28 Ici Plc Guanidino-substituted heterocyclic derivatives having histamine h-2 antagonist activity
DE3267110D1 (en) * 1981-05-18 1985-12-05 Ici Plc AMIDINE DERIVATIVES
JPS6229566A (en) * 1985-07-30 1987-02-07 Taiyo Yakuhin Kogyo Kk Novel guanidinomthylbenzoic acid derivative
US4948901A (en) * 1988-05-24 1990-08-14 Pfizer Inc. Benzamide protease inhibitors
US4874864A (en) * 1988-05-24 1989-10-17 Pfizer Inc. Benzamide protease inhibitors
US4948891A (en) * 1988-05-24 1990-08-14 Pfizer Inc. Benzamide protease inhibitors
US5055479A (en) * 1988-06-16 1991-10-08 Sankyo Company, Limited Method of treating cachexia
US5543399A (en) * 1989-08-22 1996-08-06 Hsc Research & Development Limited Partnership Cystic fibrosis transmembrane conductance regulator (CFTR) protein
GB8926512D0 (en) * 1989-11-23 1990-01-10 Pfizer Ltd Therapeutic agents
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
CA2032420A1 (en) * 1989-12-22 1991-06-23 Akira Okuyama Guanidinobenzene derivatives
US5124328A (en) * 1990-10-11 1992-06-23 Merck & Co., Inc. Morpholine derivatives compositions and use
TW274552B (en) * 1992-05-26 1996-04-21 Hoechst Ag
WO1994021621A1 (en) * 1993-03-23 1994-09-29 Astra Aktiebolag Guanidine derivatives useful in therapy
US6027880A (en) * 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
AU682381B2 (en) * 1993-08-12 1997-10-02 Astra Aktiebolag Amidine derivatives with nitric oxide synthetase activities
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5599984A (en) * 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
US5637439A (en) * 1994-11-07 1997-06-10 Mitsubishi Paper Mills Ltd. Photographic silver halide photosensitive material and method for developing the same
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
DE19544685A1 (en) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Amino acid derivatives, medicaments containing these compounds and processes for their preparation
CA2250698A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Para-substituted phenylpropanoic acid derivatives as integrin antagonists
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5766877A (en) * 1996-05-10 1998-06-16 Amgen Inc. Genes encoding art, an agouti-related transcript
US6127343A (en) * 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6287763B1 (en) * 1996-06-10 2001-09-11 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
ZA979701B (en) * 1996-10-31 1998-05-21 Novo Nordisk As Novo Nordisk A Constrained somatostatin agonists and antagonists.Constrained somatostatin agonists and antagonists.
CA2272640C (en) * 1996-11-25 2003-07-08 The Procter & Gamble Company Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US5963530A (en) * 1997-11-13 1999-10-05 Ward; Vera CD recording device with auxillary input
WO2000033813A1 (en) * 1998-12-09 2000-06-15 Chiron Corporation Administration of neurotrophic agents to the central nervous system
WO2000047207A1 (en) * 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
AU766191B2 (en) * 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
GB0019359D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
US7456183B2 (en) * 2001-04-09 2008-11-25 Novartis Vaccines And Diagnostics, Inc. Guanidino compounds
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
AU2003219914A1 (en) * 2002-02-25 2003-09-09 Chiron Corporation Intranasal administration of mc4-r agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127381A (en) * 1998-04-28 2000-10-03 Basu; Amaresh Isoquinoline compound melanocortin receptor ligands and methods of using same
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US20020137939A1 (en) * 2000-08-31 2002-09-26 Renhowe Paul A. Novel guanidinobenzamides

Also Published As

Publication number Publication date
JP2005524649A (en) 2005-08-18
AU2003219914A8 (en) 2003-09-09
EP1487474A4 (en) 2006-11-29
WO2003072056A2 (en) 2003-09-04
US20030229025A1 (en) 2003-12-11
AU2003219914A1 (en) 2003-09-09
US20070004743A1 (en) 2007-01-04
EP1487474A2 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
WO2003072056A3 (en) Intranasal administration of mc4-r agonists
WO2007093791A3 (en) Delivery device and method
MXPA03011264A (en) Nasal devices.
WO2003090812A3 (en) Nasal devices
WO2009102976A3 (en) Aerosol therapy device with high frequency delivery
AU2003267261A1 (en) Device for delivering a viscous medical solution to the nasal membrane and method for using same
WO2005055945A3 (en) Mucoadhesive drug delivery devices and methods of making and using thereof
WO2008122791A3 (en) Nasal delivery
WO2004004814A3 (en) Nasal devices
WO2002068030A3 (en) Nasal devices
EG23719A (en) New process for the synthesis of (I S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and addition salts thereof, and application in the synthesis of I V abradine and addition salts thereof witha pharmaceutically acceptable acid
EP1487992A4 (en) Central airway administration for systemic delivery of therapeutics
AU2002340032A1 (en) Method of hydration ; infusion packet system(s), support member(s), delivery system(s), and method(s) ; with business model(s) and method(s)
MXPA05008909A (en) Intranasal formulation of rotigotine.
NO20022850L (en) Storage system for drugs in powder form, as well as inhaler provided with this
WO2006129305A3 (en) A vibrating device for treating nasal congestion and sinusitis symptoms and method thereof
WO2005082925A3 (en) Novel steroid agonist for fxr
WO2004021968A3 (en) Solution for ungual application
TNSN05046A1 (en) Method of preparing dry powder inhalation compositions
DE60041658D1 (en) COMPOSITION FOR PROMOTING TISSUE FLOW
WO2004060433A3 (en) Delivery devices
HRP20090245T1 (en) Pyy agonists and uses thereof
UA85574C2 (en) Topical agent against endoparasites
WO2007091267A3 (en) Pulmonary delivery of alpha-i proteinase inhibitor
ZA200710157B (en) Container with a hollow needle

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003570803

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003716199

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003716199

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007004743

Country of ref document: US

Ref document number: 10505159

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10505159

Country of ref document: US